Spots Global Cancer Trial Database for Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Official Title: A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer
Study ID: NCT02516670
Study Description
Brief Summary: This randomized phase II trial studies how well docetaxel works when given with or without ascorbic acid in treating patients with prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ascorbic acid (vitamin C) is a water-soluble vitamin that may help inhibit the growth of cancer cells. It is not yet known whether docetaxel works better when given with or without ascorbic acid in treating prostate cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Sibley Memorial Hospital, Washington, District of Columbia, United States
Anne Arundel Health System, Research Institute, Annapolis, Maryland, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
University Hospitals of Cleveland Seidman Cancer Center, Cleveland, Ohio, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Contact Details
Name: Channing Paller, MD
Affiliation: Johns Hopkins University/Sidney Kimmel Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
